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rheumatoid arthritis; SF-36 = Short Form-36; TNF = tumor necrosis factor; VAS = visual analog scale.
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Introduction
The spondyloarthropathies are chronic, autoimmune,
inflammatory joint diseases that are second in prevalence
to rheumatoid arthritis (RA) among the rheumatic diseases
[1,2]. The seronegative (that is, negative for autoantibodies)
spondyloarthropathies include ankylosing spondylitis (AS),
psoriatic arthritis, Reiter’s syndrome (reactive arthritis),
arthritis associated with inflammatory bowel disease, and
undifferentiated spondyloarthropathies [3]. A special study
group/committee of pathologists of the European League
Against Rheumatism has recommended the term spondylo-
arthritides on the basis of the inflammatory nature of these
rheumatic conditions [4]. AS, the prototypical spondylo-
arthropathy, is an often painful disorder that impairs
physical functioning and can lead to lost productivity, loss
of employment, and impaired quality of life [5–7]. Patients
with AS have a 1.5–4-fold increased risk of death from a
variety of disorders including circulatory diseases,
amyloidosis, fractures of the spine, gastrointestinal
diseases, and renal disorders [8–10]. Prevalence varies
with ethnic origin and is highest among Native Americans
living along the Pacific Coast and among Eskimos [11].
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Abstract
Ankylosing spondylitis (AS) is a member of the family of spondyloarthropathies, which are inflammatory
arthritides largely involving the axial skeleton and commonly accompanied by peripheral arthritis.
Genetic factors, particularly the presence of HLA-B27, are major contributors to the susceptibility for
AS. Despite some therapeutic advances, the treatment options for patients with AS and related
disorders have been limited. Several lines of evidence have led to the hypothesis that patients with AS
might benefit from treatment with tumor necrosis factor (TNF). Specifically, TNF concentrations are
known to be significantly elevated in the synovium of patients with rheumatoid arthritis (RA), in the
inflamed gut of patients with inflammatory bowel disease, and in the inflamed sacroiliac joints of
patients with AS. The anti-TNF agents have been shown to be of benefit in, and currently have
indications for, RA (etanercept, infliximab, adalimumab), Crohn’s disease (infliximab), and psoriatic
arthritis (etanercept). Because the spondyloarthropathies share pathogenetic mechanisms with the
above-specified disease states, studies have been conducted to evaluate the effectiveness of anti-TNF
agents in several disorders, including AS. Data from clinical trials so far with infliximab and etanercept
show that patients with AS and related disorders achieve significant improvement in clinical signs and
symptoms based on validated outcomes measures. Computed tomography and magnetic resonance
imaging (MRI) can facilitate the early diagnosis of AS. Studies with infliximab using MRI together with
updated scoring methods demonstrated significant decreases in associated spinal inflammation. TNF
antagonist therapy is well tolerated in patients with AS, with a side effect profile consistent with the
prior experience of patients with RA.
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Genetic factors are the major contributor to AS, and
although the disease seems to be polygenic, the antigen
HLA-B27 is present in at least 75% of patients with AS
[3,12,13]. AS is believed to result from the generation of
cytokines by antigen-stimulated T cells. Pathologic changes
consist of an enthesopathy with edema and mononuclear
cell infiltration at the contact sites between bones and
ligaments or tendons [14]. Synovial tissue of the involved
joints demonstrates the proliferation of synovial lining
cells, a mononuclear cell infiltrate that can include large
numbers of plasma cells, and superficial fibrin deposition
[15]. Immunohistochemical techniques show dense
cellular infiltrates consisting predominantly of T cells and
macrophages in the sacroiliac joints of patients with AS
[16]. Large amounts of mRNA specific to tumor necrosis
factor (TNF), a proinflammatory cytokine, are found in sites
of bony remodeling in these patients, as demonstrated by
in situ hybridization analysis (Fig. 1) [16].
Elevated concentrations of TNF mRNA are found in the
synovial tissue of patients with RA [17,18], in the inflamed
gut of patients with Crohn’s disease (CD) [19], and in the
inflamed sacroiliac joints of patients with AS [16,20]. TNF
antagonists have proved successful in the management of
RA and CD. Given that TNF mRNA concentrations are
elevated in the sacroiliac joint in patients with AS, it
seemed logical to test the hypothesis that TNF antago-
nists could improve outcomes in patients with AS. This
paper briefly reviews the conventional therapies for
managing AS and focuses on the evolving role of the TNF
antagonists infliximab and etanercept in the management
of AS in patients.
Presentation and management of the
spondyloarthropathies
The clinical manifestations of AS include inflammation,
back pain – which usually presents at the thoraco-lumbar
junction – and stiffness. The stiffness is worst first thing in
the morning, or with prolonged inactivity, and patients
characteristically report improvement with activity. Although
AS is traditionally considered a disease of the axial
skeleton, arthritis of the appendicular skeleton is also
common. Examination demonstrates reduced extension
and right and left lateral bending, and flexion is reduced
with later disease [21,22]. Patients may also have
decreased chest expansion and pain and/or tenderness
over the sacroiliac region or the buttocks. Involvement of
the hip, knees, and shoulders may also be detected in
about 60–80% of patients [23,24]. Although patients with
mild AS are often able to maintain full physical function, the
presence of moderate-to-severe disease can significantly
limit employment, daily activities, and quality of life [6,25].
Until recently, treatment options for AS were limited. This
was related to two factors: chronicity of the disease
before diagnosis, and lack of therapeutic agents that
could provide anything more than symptomatic relief.
Traditional treatments have consisted predominantly of
physical therapy plus the administration of nonsteroidal
anti-inflammatory drugs (NSAIDs) to decrease joint pain
and morning stiffness [26,27]. Physical therapy and
exercise can significantly improve range of motion and
relieve symptoms; regular physical conditioning and back
exercises may also help [28]. However, most patients with
active disease require regular analgesia, often with
NSAIDs [27,29]. Selective cyclo-oxygenase-2 (COX-2)
inhibitors, such as celecoxib, are effective analgesics and
may decrease the potential risk of NSAID-induced gastro-
intestinal enteropathy [30]. Chronic administration of
systemic corticosteroids is not recommended, because
they are rarely effective and serve to promote decreased
bone mineral density, although injection of a long-acting
corticosteroid into painful sacroiliac joints may relieve pain
in patients whose symptoms are refractory to NSAIDs
[31]. The disease-controlling antirheumatic therapy or
disease-modifying antirheumatic drugs sulfasalazine and
possibly methotrexate may have some efficacy, particularly
in patients with appendicular involvement [32–34].
Because TNF mRNA has been detected in the inflamed
gut and sacroiliac joints of patients with chronic
inflammatory bowel diseases and spondyloarthropathies,
including AS, this suggested an opportunity to investigate
the efficacy of TNF antagonists in these diseases [35].
Because adalimumab has only recently become available
in the USA, most of the clinical investigations have been
conducted with etanercept and infliximab. Currently, in
addition to RA, etanercept is approved in the USA for use
Figure 1
In situ hybridization analysis demonstrates large amounts of tumor
necrosis factor (TNF) mRNA, in sites of bony remodeling in a patient
with ankylosing spondylitis. TNF is a proinflammatory cytokine.
Reproduced with permission from John Wiley & Sons, Inc. [16]. 
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in psoriatic arthritis, whereas infliximab is indicated for CD
[3,36,37].
Etanercept and infliximab: similar yet different
Although etanercept and infliximab are both anti-TNF
inhibitors, they differ in several ways. First, etanercept
binding is restricted to the trimeric form of soluble TNF,
whereas infliximab binds to both monomer and trimer forms.
Second, etanercept forms relatively unstable complexes
with soluble TNF, resulting in the release of dissociated
TNF, whereas infliximab forms stable complexes with
soluble TNF. Third, more infliximab molecules bind to
transmembrane TNF, and with a higher avidity than
etanercept [38]. Knowledge of binding characteristics
differences may explain some of the differences seen with
infliximab and etanercept in Crohn’s disease, a member of
the spondyloarthropathy family. For example, infliximab has
been shown to be effective in both short-term [39] and
long-term [40] clinical trials in CD, and to continue these
benefits with maintenance infliximab treatment, but the
efficacy of etanercept in CD, in a well-controlled
randomized trial, has not been demonstrated [35,41].
With infliximab, 573 patients with active CD who
continued infliximab after an initial response to a single
infusion were more likely to be in remission at weeks 30
and 54, whereas results from the study by Sandborn and
colleagues [41] showed no statistically significant difference
between the percentage of etanercept-treated patients
and that of control-treated patients who showed improve-
ment at 4 weeks on the CD Activity Index (39% versus
45%, P = 0.763, respectively). Factors postulated to be
responsible for these differences include the following: the
maintenance of stable neutralizing complexes with TNF
[38]; the accessibility of involved tissues to the agent
depending on the administered dose; the potential role of
other cytokines, such as lymphotoxin-α, in certain disease
processes; the concentration of TNF in the involved
tissues; and the relative sensitivity of affected tissues to
the effects of TNF [38]. It is important to state that
whereas these differences exist in CD, there are no direct
comparisons in CD or in AS. Whether the differences in
CD translate to differences in AS is not yet known. We
now turn our attention to patients with AS and a review of
some of the early and pivotal trial data with these agents.
Etanercept
Gorman and colleagues [42] conducted a double-blind,
placebo-controlled trial to evaluate the effectiveness of
etanercept in 40 patients with active, inflammatory AS.
Patients were randomized to receive etanercept 25 mg
subcutaneously twice weekly or placebo for 4 months,
with the opportunity to participate in a 6-month open-label
extension in which all patients would receive etanercept
[43]. The primary outcome measure was a composite
treatment response of 20% or more in at least three of five
measures of disease activity, which is similar to the criteria
defined by the Assessments in Ankylosing Spondylitis
(ASAS) Working Group [44] – duration of morning stiffness,
degree of nocturnal spinal pain, the Bath Ankylosing
Spondylitis Functional Index (BASFI) [45], the patient’s
global assessment of disease activity, and the joint
swelling score – with no worsening in any measure.
At the end of 4 months, treatment response was originally
reported in 80% of etanercept-treated patients versus
30% of controls (P = 0.004) [42]. A subsequent re-
analysis corrected this to 75% instead of 80%, with a
corrected  P value of 0.01 by Fisher’s exact test (two-
tailed) [46]. Other results at 4 weeks included changes in
physicians’ global assessment of disease activity (–31.5
with etanercept versus +7.5 with placebo, P < 0.001),
patients’ global assessment of disease activity (–1.0 with
etanercept versus 0 with placebo, P < 0.001), BASFI (–2.3
with etanercept versus –0.1 with placebo, P < 0.001),
erythrocyte sedimentation rate (ESR) (–26.0 mm/h with
etanercept versus –3.5 mm/h with placebo, P < 0.001), and
C-reactive protein (CRP) (–1.3 mg/dL with etanercept
versus +0.5 mg/dL with placebo, P = 0.003), where lower
scores represent better outcomes for all measures
evaluated. With regard to spinal mobility, one measure
showed significant improvement (greater chest expansion
by 0.9 cm at 4 months with etanercept versus less
expansion by 0.2 cm with placebo, P = 0.006), whereas
no statistically significant difference was seen for two
measures at 4 months: modified Schober’s index
(P = 0.26) and occiput-to-wall measurement (P = 0.11).
This may have been due to spinal ossifications related to
prolonged disease. The measure of enthesitis used in this
study, the modified Newcastle Enthesis Index [47,48],
showed significant improvement after 4 months (–4.5 with
etanercept versus –1.5 with placebo, P = 0.001), although
the authors suggest that the measure requires further
study [42]. In terms of overall efficacy, the authors con-
cluded that etanercept produced a rapid, significant, and
sustained response in the initial phase of the study [42].
The 6-month open-label phase that followed showed that
etanercept sustained clinical benefit in terms of percentage
of patients achieving an ASAS 20% response up to the
end of the study (Fig. 2) [42,43]. Etanercept was well
tolerated, with five injection-site reactions (versus one with
placebo) and 10 cases of upper respiratory infections
(versus 12 with placebo) being the most commonly reported
adverse events [42]. Other adverse events included
tinnitus and muscle fasciculations of eye and thigh muscles
reported in one etanercept-treated patient, and the
development of a positive antinuclear antibody titer of 1:80
in one etanercept-treated and one placebo-treated patient.
In another placebo-controlled, double-blind, 24-week trial
of etanercept, 30 patients with proven, active AS wereS39
randomized to initially receive etanercept 25 mg sub-
cutaneously twice a week or placebo for 6 weeks [49].
After 6 weeks, the placebo-treated patients were crossed
over to receive etanercept for 12 weeks, and the etanercept-
treated patients were continued on medication for an
additional 6 weeks. Primary outcome measures were
indices of disease activity including the Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI) [50], the
BASFI, pain, quality of life (measured by the Short Form-36
[SF-36]) [51], and concentrations of CRP [49]. By
definition, responders showed a 50% or more improve-
ment in the BASDAI score. Results at 6 weeks showed a
50% BASDAI response in 57% of etanercept-treated
patients versus 6% of controls (P = 0.004) [49]. Similar
results were reported in the patients who switched to
etanercept after 6 weeks of placebo. Significant improve-
ments were also seen in physical function (P < 0.05) and
mean concentrations of CRP (P < 0.001). No severe
adverse events or major infections were reported.
Infliximab
To evaluate the effectiveness of infliximab in patients with
AS, an open-label pilot study was conducted in which 11
patients with AS of short duration (median 5 years) and
active disease for at least 3 months were administered
three infusions of infliximab 5 mg/kg intravenously at weeks
0, 2, and 6 [52]. Follow-up assessments were made at
weeks 1, 2, 4, 6, 8, and 12. Outcome measures included
BASDAI, BASFI, pain as measured on a 10-cm visual
analog scale (VAS), and the Bath AS Metrology Index
(BASMI), which is used to assess spinal mobility [52,53].
Laboratory markers (such as CRP, ESR, and interleukin-6)
were monitored, and dynamic magnetic resonance
imaging (MRI) was performed in five patients. Of the 11
patients at study entry, 10 continued until completion of
the study at 12 weeks, with all showing a marked improve-
ment in all parameters compared with baseline (based on
median values): BASDAI (2.4 versus 6.5, P = 0.004),
BASFI (2.4 versus 5.3, P = 0.008), BASMI (1.5 versus
3.0, P = 0.1), VAS for pain (2.5 versus 7.8, P = 0.004),
CRP (less than 6.0 versus 15.5 mg/L, P = 0.008), and
ESR (<15.0 versus 32.0 mm/h, P = 0.008) [52]. Median
interleukin-6 concentrations also declined from 12.4 mg/L
at baseline to less than 5 mg/L at week 12. Subjective
improvement was noted as early as 1 day after the initial
infusion, with the positive effect persisting until week 12.
Three of five patients had MRI-revealed spinal inflammation
at baseline, which improved in two of the three patients
2–6 weeks after the third infusion. This study gave a very
positive early indication that anti-TNF therapy is effective in
the management of AS over the short term.
The successful results of the 12-week open-label phase
led to an extension phase in which patients were to be
given up to three additional infusions of infliximab 5 mg/kg
in cases of relapse [54]. The median total observation
period for the open-label phase was 39 weeks (range
35–41 weeks); by the end of the study, six patients had
received all three additional infliximab infusions. The data
from this study, which was the first to report on the long-
term (approximately 1 year) management of active AS with
infliximab, showed that the improvement elicited by a
loading regimen of three infliximab infusions could be
maintained for up to about 7 weeks before the first
symptoms reappeared [54]. Dosing data suggested that
infliximab infusions might be needed every 6 weeks to
achieve sustained improvement in patients with active AS.
A placebo-controlled 12-week study involving 70 patients
with active AS was conducted to assess the effectiveness
of infliximab in AS [55]. The patients were randomized to
receive either infliximab 5 mg/kg at weeks 0 (baseline), 2,
and 6, or placebo. Efficacy parameters included validated
clinical criteria from the ASAS working group [44] (namely
BASDAI, BASFI, BASMI, and SF-36 for quality of life). The
primary end point was a 50% improvement in disease
activity, as determined by BASDAI, at the study’s end
(week 12). Intention-to-treat analysis showed more
patients meeting the primary end point (BASDAI 50%)
with infliximab than with placebo (53% versus 9%,
P < 0.0001) [55]. Throughout the 12-week treatment
period, infliximab was shown to be effective in terms of the
percentage of patients achieving response for all the
response criteria used: BASDAI 20% (P = 0.001),
Available online http://arthritis-research.com/content/6/S2/S36
Figure 2
Percentage of patients in each study group who had a treatment
response. A treatment response was defined as 20% or greater
improvement in at least three of five outcome measures (duration of
morning stiffness, degree of nocturnal spinal pain, the Bath Ankylosing
Spondylitis Functional Index, the patient’s global assessment of
disease activity, and the score for joint swelling). The patients in the
etanercept group received etanercept throughout the 10-month study
period; those in the placebo group received placebo for 4 months,
followed by etanercept for 6 months. The differences between the
groups were statistically significant at month 1 (P < 0.001), month 3
(P = 0.03), and month 4 (P = 0.004). During the open-label portion of
the trial, there were no statistically significant differences between the
two groups. Reproduced with permission from [42]. Copyright ©
2002 Massachusetts Medical Society. All rights reserved. Note that
subsequent reanalysis of the data the end of 4 months corrected the
P value to 0.001 [46].
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BASDAI 70% (P = 0.045), ASAS 20% (P = 0.0007),
ASAS 50% (P < 0.0001), ASAS partial remission
(P = 0.005), BASFI (P< 0.0001), and BASMI (P= 0.0023).
Infliximab demonstrated effects on peripheral arthritis and
enthesitis. At baseline, 44% of patients in the infliximab
group had both conditions active; by week 12, only 17%
had peripheral arthritis and 27% had enthesitis. No
change was noted in the placebo-treated patients for
arthritis (P = 0.249) or enthesitis (P = 0.81). As for the
SF-36 data, infliximab significantly improved the physical
component score, whereas placebo did not (P < 0.0001).
The 67 patients in both treatment groups who completed
the study were enrolled in a 1-year open-label extension
phase in which the controls were treated with infliximab
5 mg/kg intravenously and then received infusions every
6 weeks until week 54 [56]. The magnitude of the
response at 12 weeks was sustained until week 54, with
improvement reported in every outcome measure that was
evaluated: BASDAI, BASFI, pain by VAS, quality of life by
SF-36, and CRP [56]. Figure 3 illustrates the percentage
of infliximab- and placebo-treated patients who attained
50% BASDAI improvement from baseline through to week
54. Data at 6 weeks after those initially treated with placebo
were switched to infliximab were 56% for infliximab, in
comparison with 49% for the placebo group (P value not
significant), demonstrating rapid response once the
placebo group received the active drug [56]. By the end
point of the study, 54 patients completed the course
(more than 75%); 16 patients dropped out. An analysis of
completers confirmed a continuous decline in disease
activity based on BASDAI (means ± SD are shown):
6.5 ± 1.3 at week 0, 3.2 ± 1.8 at week 12, and 2.5 ± 1.8
at week 54. This study demonstrated that infliximab remains
efficacious in active AS over a 1-year treatment period.
Other aspects of infliximab therapy in patients with AS
have been investigated. An open-label study by Stone and
colleagues (21 patients enrolled; 18 patients evaluated at
week 14) was conducted to determine whether infliximab
(5 mg/kg intravenously for 2 hours at weeks 0, 2, and 6) is
an effective treatment for patients with AS who have not
responded satisfactorily to conventional therapy and to
identify whether there are any baseline clinical and
imaging correlates of response to treatment with infliximab
in AS [57]. Measures taken at baseline and with each
subsequent visit included nine functional variables (for
example BASDAI, BASFI, and Health Assessment
Questionnaire), six clinimetrics (for example chest
expansion and finger-to-floor distance), and laboratory
inflammatory markers (for example ESR, CRP, and
haptoglobin); MRI scans before and after infusions were
performed in a subset of nine selected consecutive
patients. Results showed that by week 14 there was more
than 60% improvement in functional variables, selective
improvement in clinimetric scores (for example chest
expansion,  P < 0.021), and significant improvement in
inflammatory markers, which were maintained from week 6.
MRI findings showed improvement in the patients
examined during the imaging cohort and demonstrated a
reversal of inflammatory changes with infliximab as early as
weeks 2–4. Other key findings were the identification of
two groups of responders to infliximab (marked responders
and not so marked responders), an absence of correlation
between treatment response and baseline inflammatory
markers, and a positive benefit with infliximab even in
patients with advanced AS (as all patients in this study
had high baseline BASDAI scores).
Maksymowych and colleagues, in a prospective observa-
tional and inception cohort analysis, evaluated the efficacy
and tolerability of infliximab in 21 patients with NSAID-
refractory AS seen in both university-based and
community-based practice [58]. The patients in this study,
who were seen from April 2000 to October 2001, were
given infliximab at a dose of 3 mg/kg intravenously at
weeks 0, 2, and 6, and at 2-month intervals thereafter.
Data collected (at baseline, at week 14, and at the earlier
of year 1 or withdrawal) included patient demographics,
Bath AS indices (for example BASDAI, BASFI, and
BASMI), laboratory markers (for example ESR and CRP),
and adverse events or reasons for withdrawal; dynamic
MRI with gadolinium enhancement was also done for the
first six consecutive patients. Efficacy data from 17
patients assessed at week 14 included the following
significant results: mean BASDAI improvement from
baseline (P < 0.001), 43% reduction in mean BASFI
(P < 0.001), 55% reduction in mean ESR (P < 0.001),
63% reduction in mean CRP (P = 0.01), and reduction in
maximal rate of MRI-defined gadolinium augmentation
(P = 0.04). The study demonstrated the effectiveness and
Figure 3
Percentage of patients treated with placebo, infliximab, or placebo
followed by infliximab responding to therapy in the double-blind and
open-label phases of the study. The results are from an intention-to-
treat analysis. Reproduced with permission from John Wiley & Sons,
Inc. [56]. © 2002 American College of Rheumatology
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tolerability of infliximab, even when used at a lower dose
than used previously in AS studies, to manage both axial
and peripheral joint disease in patients with AS.
In addition to its demonstrated efficacy in AS, infliximab
has been shown to be effective in patients with other
types of spondylarthritides. Van den Bosch and
colleagues evaluated the efficacy and safety of infliximab
in a 12-week placebo-controlled clinical trial involving 40
patients with active spondyloarthropathy (AS with axial
disease, AS with peripheral arthritis, psoriatic arthritis,
undifferentiated spondyloarthropathy) [59]. Patients were
randomized to receive either placebo or infliximab 5 mg/kg
on weeks 0, 2, and 6. Primary outcome measures were
improvements in patient and physician global assess-
ments of disease activity on a 100 mm VAS. Study results
showed a statistically significant difference in favor of
infliximab for the primary outcome (global disease
assessments) and significant reductions in ESR and CRP
as early as week 2 and sustained up to week 12. For the
peripheral disease assessments, infliximab led to
significant improvements at week 12 for all outcomes
(morning stiffness, P = 0.038; peripheral joint pain,
P = 0.002; tender joint count, P = 0.015) except swollen
joint count (P value not significant). For axial disease
assessments, statistically significant improvements in favor
of infliximab were seen for morning stiffness (P = 0.006),
spinal pain (P = 0.002), BASDAI (P = 0.002), and BASFI
(P = 0.041). Given the limited numbers seen with
psoriasis and differences in baseline Psoriasis Area and
Severity Index, no conclusions could be drawn for any
psoriasis-specific effect. Overall, this study demonstrated
that infliximab is efficacious in various spondyloarthro-
pathies, including and other than AS.
Use of MRI to visualize spinal inflammation
Imaging techniques such as computed tomography (CT)
and MRI might extend the sensitivity of conventional
radiologic procedures in the diagnosis of early AS. CT can
detect early bony erosions, whereas MRI is particularly
sensitive to inflammatory changes in the soft tissue and
bone marrow (Fig. 4) [60]. The sensitivity of MRI
techniques can be enhanced with the use of contrast
materials such as gadolinium. Fat-saturation techniques
such as the Short-Tau Inversion Recovery method can be
used to characterize the acute spinal inflammation of
active AS [61,62].
On the basis of the MRI results, the acute spinal lesions of
AS can be evaluated by the MRI Scoring System for
Spinal Inflammation in AS (ASspiMRI), an updated system
in which each of 24 vertebrae (C2 to S1) is graded on a
six-point scale that measures degree of edema, extent of
bone erosions, inflammation, and chronicity [63]. Braun
and colleagues employed this system in a study examining
the effects of infliximab 5 mg/kg in 20 patients with active
AS [62]. The infliximab-treated patients showed a 60%
improvement in Short-Tau Inversion Recovery scores over
3 months (P = 0.01), whereas the controls showed a 21%
deterioration from baseline (P = 0.5). Improvement in MRI
scores with infliximab was significantly correlated with
clinical improvement in BASDAI scores (P < 0.03).
Conclusion
In patients with active AS, anti-TNF therapy with infliximab
and etanercept has been shown to result in clinically
important benefits, as assessed with validated outcomes
measures. MRI studies demonstrate that improvements in
clinical parameters are accompanied by decreased
structural manifestations of disease. Future trials need to
delineate predictors of optimal patient response to anti-
TNF therapy, optimum dosing schedules, and the role of
combination therapy to enhance clinical benefit. Whether
TNF antagonist therapy alters the natural history of AS
remains an important research priority. Early therapy could
then prevent the associated disability and economic
consequences of AS.
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Figure 4
Magnetic resonance images of a normal spine (left) and spinal
inflammation in a patient with ankylosing spondylitis (right).
Reproduced with permission from Elsevier [60].S42
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